A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session7barre91h1flqmhcik6uahmd3gr2dn7c): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience. | LitMetric

AI Article Synopsis

  • Cefiderocol is an innovative antibiotic showing effectiveness against carbapenem-resistant Gram-negative bacteria, but more postmarketing data was needed to evaluate its real-world use.
  • A study involving 142 patients from three Italian hospitals found a 30-day mortality rate of 37%, with comorbidities being a key predictor of poor outcomes, while polymicrobial infections seemed to have a protective effect.
  • There was no significant difference in mortality rates between those treated with cefiderocol alone and those given combination therapies, suggesting cefiderocol can serve as a viable monotherapy option.

Article Abstract

Background: Cefiderocol is a novel siderophore cephalosporin with promising activity against most carbapenem-resistant Gram-negative bacteria (CRGNB). However, extensive postmarketing experiences are lacking. This study aimed to analyse the early experience on cefiderocol postmarketing use at three tertiary care hospitals in Italy.

Methods: We retrospectively included patients with infections caused by CRGNB treated with cefiderocol at three Italian tertiary care hospitals from 1 March 2021 to 30 June 2022. A multivariate Cox model was used to identify predictors of 30 day mortality. A propensity score (PS) analysis with inverse probability weighting (IPW) was also performed to compare the treatment effect of cefiderocol monotherapy (CM) versus combination regimens (CCRs).

Results: The cohort included 142 patients (72% male, median age 67 years, with 89 cases of Acinetobacter baumannii infection, 22 cases of Klebsiella pneumoniae, 27 cases of Pseudomonas aeruginosa and 4 of other pathogens). The 30 day all-cause mortality was 37% (52/142). We found no association between bacterial species and mortality. In multivariate analysis, a Charlson Comorbidity Index >3 was an independent predictor of mortality (HR 5.02, 95% CI 2.37-10.66, P < 0.001). In contrast, polymicrobial infection (HR 0.41, 95% CI 0.21-0.82, P < 0.05) was associated with lower mortality. There was no significant difference in mortality between patients receiving CM (n = 70) and those receiving a CCR (n = 72) (33% versus 40%, respectively), even when adjusted for IPW-PS (HR 1.11, 95% CI 0.63-1.96, P = 0.71).

Conclusions: Real-life data confirm that cefiderocol is a promising option against carbapenem-resistant Gram-negative infections, even as monotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631827PMC
http://dx.doi.org/10.1093/jac/dkad298DOI Listing

Publication Analysis

Top Keywords

carbapenem-resistant gram-negative
8
gram-negative bacteria
8
tertiary care
8
care hospitals
8
cefiderocol
5
cefiderocol treatment
4
treatment infections
4
infections carbapenem-resistant
4
bacteria italian
4
italian multicentre
4

Similar Publications

Cefiderocol (FDC), a siderophore-cephalosporin conjugate, is the newest option for treating infection with carbapenem-resistant gram-negative bacteria. We identified a novel mechanism contributing to decreased FDC susceptibility in Klebsiella pneumoniae clinical isolates. The mechanism involves 2 coresident plasmids: pKpQIL, carrying variants of bla carbapenemase gene, and pKPN, carrying the ferric citrate transport (FEC) system.

View Article and Find Full Text PDF

Nosocomial bloodstream infections with multidrug-resistant microorganisms have become a common health threat in intensive care settings worldwide. Understanding antimicrobial resistance and the outcomes of these infections is crucial for addressing this issue. This study aimed to investigate the burden, antimicrobial resistance, and 28-day outcomes of nosocomial bloodstream infections in the intensive care unit.

View Article and Find Full Text PDF

Background: For resistant Gram-positive bacteria, evidence suggests that combination therapy is more effective. However, for resistant Gram-negative bacteria, no consensus has been reached. This study aims to comprehensively summarize the evidence and evaluate the impact of combination versus monotherapy on infections caused by carbapenem-resistant Gram-negative bacteria (CRGNB).

View Article and Find Full Text PDF

Treatment of severe carbapenem-resistant Pseudomonas aeruginosa infections: still many uncertainties.

Lancet Infect Dis

December 2024

INSERM, IAME, U1137, Team DeSCID, Paris, France; Assistance Publique Hôpitaux de Paris, Medical and Infectious Diseases ICU, Bichat Hospital, F75018 Paris, France; OUTCOME REA Research Group, Drancy, France. Electronic address:

View Article and Find Full Text PDF

Unlabelled: There is a critical need for treatment strategies to combat carbapenem-resistant Gram-negative pathogens. This study investigates the efficacy of combining low concentrations of colistin with tigecycline against colistin- and carbapenem-resistant and strains. We used two strains of KPC-2-producing and OXA-23-producing , both of which are highly colistin-resistant.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!